AC
BMRN icon

Amici Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Amici Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-45,000
Closed -$3.73M – 5
2016
Q4 		$3.73M Buy
+45,000
New +$3.87M 1.45% 24
2016
Q2 		– Sell
-32,000
Closed -$2.64M – 125
2016
Q1 		$2.64M Buy
+32,000
New +$2.6M 0.31% 61
2015
Q2 		– Sell
-375,000
Closed -$46.7M – 141
2015
Q1 		$46.7M Buy
+375,000
New +$39.7M 1.68% 20

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Amici Capital's BMRN Position: Q1 2017 in Review

Amici Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 409,818 shares — an estimated $33.9M sold.

Amici Capital first reported a position in BMRN in Q2 2013 and held it in 15 quarters. The position peaked at $203M in Q2 2015. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

  • Amici Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Amici Capital sold 409,818 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $33.9M.
  • Amici Capital first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Amici Capital's BioMarin Pharmaceuticals position peaked at $203M in Q2 2015.
  • 418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Amici Capital's 13F filing for Q1 2017.